Library.

“Thousands of people have reported severe side effects from Ozempic (semaglutide), including blindness and organ damage.”

The claim is broadly supported as a description of adverse-event reporting, not confirmed causation. Safety databases contain thousands of serious semaglutide reports, and those reports include blindness or vision-loss terms as well as kidney and liver injury. The main caveat is that these are reported events, often across semaglutide products, and do not by themselves prove Ozempic caused each case.

“Novo Nordisk is facing a lawsuit seeking US$2 billion in damages related to Ozempic.”

Novo Nordisk is indeed facing Ozempic-related lawsuits, but the evidence does not show a single lawsuit seeking US$2 billion in damages. The "$2 billion" figure is reported as an aggregate estimate of potential liability or payouts across many cases, not as the demand in one specific complaint. The claim is therefore not supported as stated.

“Use of Ozempic is associated with changes in taste perception and reduced enjoyment of eating.”

Mostly True. Clinical research and patient data consistently show that Ozempic (semaglutide) use is associated with changes in taste perception — roughly one in five users report heightened sweet or salty sensitivity, supported by studies documenting altered tongue gene expression and brain responses. The "reduced enjoyment of eating" component is less rigorously established, relying more on patient reports and media accounts than controlled hedonic measurements, but it is not unsupported. The claim is directionally accurate but somewhat overstates the enjoyment dimension.

“Ozempic and similar GLP-1 drugs have contributed to a reduction in United States obesity rates for the first time in decades.”

U.S. adult obesity rates have indeed declined modestly — from roughly 42.8% (2017–2018) to about 40.3% (2021–2023) per CDC data, with Gallup surveys showing a further drop to ~37% by 2025. This coincides with a dramatic surge in GLP-1 drug use (30+ million Americans by 2025). Experts widely identify GLP-1 drugs as a plausible contributing factor, but no study has confirmed a direct causal link at the population level. The decline is also uneven — rural obesity actually rose — and other factors like post-COVID behavioral changes haven't been ruled out.

“The use of weight-loss drugs such as Ozempic and Wegovy will significantly impact public health outcomes by 2036.”

The claim is largely supported. High-quality peer-reviewed studies project that GLP-1 drugs like Ozempic and Wegovy could avert tens of thousands of deaths annually and prevent over a million cardiovascular events within the 2036 timeframe. Clinical efficacy is well-established, and early population-level signals are emerging. However, these projections depend on expanded access, sustained adherence, and affordability improvements that are not yet guaranteed — and high costs and coverage gaps could limit who benefits and worsen health disparities.